How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01616 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434058 How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies Patrick M. Reagan, MD1xPatrick M. ReaganSearch for articles by this author and Sattva S. Neelapu , MD2xSattva S. NeelapuSearch for articles by this author Show More 1Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.20.01616 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveIs it possible to make access to chimeric antigen receptor T cells widely available?Knowledge GeneratedStandardized grading scales for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome have been developed for use in trials and clinical practice, and early studies have provided insight into the pathophysiology of these toxicities. Current management of toxicity is based on prospective studies, but randomized comparisons of management strategies are lacking.RelevanceAdoption of a common grading scale and standardization of toxicity management can facilitate the use of chimeric antigen receptor T cells across academic and community sites.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTHow I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell TherapiesThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Patrick M. ReaganConsulting or Advisory Role: Curis, Kite PharmaResearch Funding: Seattle GeneticsSattva S. NeelapuHonoraria: Bio Ascend, Medscape, Aptitude Health, MJH Life SciencesConsulting or Advisory Role: Merck Sharp & Dohme, Celgene, Kite Pharma, Novartis, Unum Therapeutics, Cell Medica, Incyte, Gilead Sciences, Pfizer, Precision Biosciences, Allogene, Legend Biotech, Bristol Myers Squibb, Adicet Bio, CalibrResearch Funding: Bristol Myers Squibb, Merck Sharp & Dohme, Kite Pharma, Acerta Pharma, Cellectis, Poseida Therapeutics, Karus Therapeutics, Unum Therapeutics, Gilead Sciences, Allogene, Precision BiosciencesPatents, Royalties, Other Intellectual Property: Patents related to cellular therapy, Royalty income from Takeda PharmaceuticalsTravel, Accommodations, Expenses: Medscape, Kite Pharma, Gilead Sciences, Merck, Unum Therapeutics, Celgene, Chugai Pharma, Precision Biosciences, Novartis, Pfizer, Allogene, Legend BiotechNo other potential conflicts of interest were reported.